Celebrating 20 years at axogen


celebrating 20 years at axogen
This year, Axogen celebrates its 20th anniversary of revolutionizing the science of nerve repair and helping to improve quality of life and restore feeling and functionality to patients with damaged peripheral nerves.

Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Axogen’s comprehensive portfolio of products continues to help patients regain the ability to kiss, smile, hug, walk, eat, touch, run, feel—some of the many things healthy peripheral nerves allow us to do.

We are celebrating our role as the leading company specifically dedicated to improving quality of life for patients suffering from peripheral nerve injuries and our 20 years of unwavering focus on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.

Celebrating 20 years at axogen

our commitment to our mission

Our dedication to improved patient outcomes has been at the core of our business since our founding in 2002, and today it fuels Axogen’s innovative product portfolio, physician education initiatives, clinical research, and patient awareness campaigns.

We have continued to expand applications and increase adoption of our platform for nerve repair, simultaneously growing our business and the market in pursuit of our mission.

Read Patient stories

our clinical innovation

Axogen is a company built on science and innovation – they are common threads woven throughout our 20-year history and across our company. As we continue to grow, our corporate reputation is anchored by innovation. Learn about how our clinical studies are advancing peripheral nerve science.

learn more

key milestones

Check out some of our key milestones and proudest moments from the past 20 years:

  • 2002

    Axogen is founded

  • 2003

    Axogen licensed technology from the University of Florida and the University of Texas Austin

  • 2006

    Axogen receives first VC funding, opens dedicated labs for peripheral nerve research at the Biotech Development Incubator of UF, and creates Axogenic values

  • 2007

    First implant of Avance® Nerve Graft at Mayo Clinic

  • 2008

    RANGER® registry is initiated

  • 2009

  • 2010

    U.S. FDA grants enforcement discretion letter for Avance

  • 2011

    Axogen becomes public company (AXGN)

  • 2013

    Axogen expands into oral & maxillofacial (OMF) market and begins the MATCH® study

  • 2014

    Burleson, TX distribution center opens

  • 2015

    First implant made in RECONSM study and Dayton, OH processing center opens

  • 2018

    Axogen expands into breast neurotization with Resensation®, launches patient website, and receives RMAT designation for Avance® Nerve Graft

  • 2019

    Axogen achieves $100+ million in annual revenue, expands sales team to over 100 reps, and 100th peer-reviewed clinical paper featuring Axogen technologies is published

  • 2020

    Axogen expands into the surgical treatment of pain, reaches RECON study enrollment, publishes key RANGER and MATCH study data, and opens Tampa office and research labs

  • 2021

    REPOSESM study completes pilot phase

  • 2022

    Axogen announces positive topline results from Phase 3 RECON study for Avance, publishes REPOSE pilot study results, and initiates REPOSE-XLSM study